Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vascular Closure Devices at the Crossroads

Executive Summary

There are some 15 million medical procedures performed worldwide each year using interventional, catheter-based techniques, and that number will grow as the aging population demands less invasive treatments. This revolution has already generated multibillion dollar product markets for the devices used to perform these procedures, but there is another huge, frequently overlooked opportunity: devices for closing the puncture site.

You may also be interested in...



Innovation And Under-Penetration Driving Global Vascular Access Markets

With an annual growth of almost 5%, the market for vascular access site repair products is attracting companies with innovative new products. Wider acceptance of new approaches to wound closure by interventionalists and the under-penetration in emerging Asian markets in particular are resulting in an uptake in the use of higher-tech devices and the emergence of local manufacturers.

Heart Valve Market: PAVR Poised for Growth

Much like the early days of coronary stenting, percutaneous aortic valve replacement has captured the imagination of physicians and industry alike. Although many challenges remain, most physicians in the heart valve community appear optimistic that transcatheter aortic valve technologies will eventually achieve a prominent place in the treatment armamentarium, a development that would put these devices on track to achieve over $1 billion in sales within the next five years.

Vascular Access Closure Ten Years Later: Why Start-Ups Can't Seal the Deal

Despite the best intentions and brightest innovation, start-ups haven't been able to tap into the huge potential presented by the vascular closure market. Ten years after the first generation devices made it to market, the original two leaders still dominate despite the limitations of their devices, while many start-ups have come and gone. A long list of new hopefuls believe they have the solution physicians have desired. Now all they have to do is convince the physicians, who, when it comes to vascular closure devices, are slow to recognize clinical data but quick to embrace a device that feels right to them.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel